- Home
- QLGN vs SILO Comparison
QLGN vs SILO Comparison
Compare QLGN & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- SILO
- Stock Information
- Founded
- QLGN 1996
- SILO 2010
- Country
- QLGN United States
- SILO United States
- Employees
- QLGN N/A
- SILO N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- QLGN Health Care
- SILO Consumer Discretionary
- Exchange
- QLGN Nasdaq
- SILO Nasdaq
- Market Cap
- QLGN 7.4M
- SILO 8.0M
- IPO Year
- QLGN N/A
- SILO N/A
- Fundamental
- Price
- QLGN $3.06
- SILO $0.56
- Analyst Decision
- QLGN
- SILO
- Analyst Count
- QLGN 0
- SILO 0
- Target Price
- QLGN N/A
- SILO N/A
- AVG Volume (30 Days)
- QLGN 3.7M
- SILO 859.7K
- Earning Date
- QLGN 11-13-2025
- SILO 11-11-2025
- Dividend Yield
- QLGN N/A
- SILO N/A
- EPS Growth
- QLGN N/A
- SILO N/A
- EPS
- QLGN N/A
- SILO N/A
- Revenue
- QLGN N/A
- SILO $72,102.00
- Revenue This Year
- QLGN N/A
- SILO $1.86
- Revenue Next Year
- QLGN N/A
- SILO N/A
- P/E Ratio
- QLGN N/A
- SILO N/A
- Revenue Growth
- QLGN N/A
- SILO N/A
- 52 Week Low
- QLGN $1.61
- SILO $0.40
- 52 Week High
- QLGN $8.81
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- QLGN 40.62
- SILO 41.12
- Support Level
- QLGN $2.90
- SILO $0.53
- Resistance Level
- QLGN $5.97
- SILO $0.62
- Average True Range (ATR)
- QLGN 0.54
- SILO 0.06
- MACD
- QLGN -0.20
- SILO -0.01
- Stochastic Oscillator
- QLGN 5.21
- SILO 54.50
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.